We also demonstrated that in in vivo experiments in mice, meloxicam combined with PD1 monoclonal antibody is more effective than traditional monotherapy in the treatment of HCC, and it has a very strong clinical application potential for PD1-resistant patients. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.